PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
alpelisib Sensitive: A1 - Approval
|
alpelisib Sensitive: A1 - Approval
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline
|
CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
CDK4 inhibitor + alpelisib Sensitive: A2 - Guideline
|
CDK4 inhibitor + alpelisib Sensitive: A2 - Guideline
|
PIK3CA mutation + HR positive
|
Hormone Receptor Positive Breast Cancer
|
PIK3CA mutation + HR positive
|
Hormone Receptor Positive Breast Cancer
|
alpelisib Sensitive: C1 - Off-label
|
alpelisib Sensitive: C1 - Off-label
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
GDC-0077 Sensitive: C2 – Inclusion Criteria
|
GDC-0077 Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
palbociclib + GDC-0077 Sensitive: C3 – Early Trials
|
palbociclib + GDC-0077 Sensitive: C3 – Early Trials
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
alpelisib + GDC-0032 Sensitive: C3 – Early Trials
|
alpelisib + GDC-0032 Sensitive: C3 – Early Trials
|
PIK3CA mutation + HR positive
|
HER2 Positive Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Positive Breast Cancer
|
trastuzumab Resistant: C3 – Early Trials
|
trastuzumab Resistant: C3 – Early Trials
|
PIK3CA mutation + HR positive
|
HER2 Positive Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
CDK4 inhibitor Resistant: C3 – Early Trials
|
CDK4 inhibitor Resistant: C3 – Early Trials
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
CDK6 inhibitor Resistant: C3 – Early Trials
|
CDK6 inhibitor Resistant: C3 – Early Trials
|